IL2 and cancer: Since the middle of 1990s, IFN-α and IL-2 have long been used separately or in combination in the treatment for malignancies, to evoke stronger antitumor immune response as immune modulators or to stimulate immune cells as growth factors, but the clinical antitumor outcomes were limited [37, 38].